

Marshall Fordyce, M.D.

Dr. Marshall Fordyce is Associate Director of Clinical Research at Gilead Sciences, where his current research focuses on the development of novel tenofovir prodrugs for the treatment of HIV infection. Previously, Dr. Fordyce was Instructor in Clinical Medicine and Clinical Scholar at The Rockefeller University, and Research Fellow at the Aaron Diamond AIDS Research Center, where under Dr. David Ho, his research focused on the effect of the HIV entry inhibitor, ibalizumab, on the envelope protein, and the immunologic effects of initiating antiretroviral therapy during acute infection. Dr. Fordyce received his Bachelor's degree and M.D. from Harvard University. He completed his Internal Medicine Training at New York University/Bellevue Hospital, where he served as Senior Chief Resident, and completed his Infectious Disease training at Columbia Presbyterian Hospital. Dr. Fordyce is board certified in Internal Medicine and Infectious Diseases. Dr. Fordyce is a member of the Board of Directors of the Albert and Mary Lasker Foundation.